local_hospital

Centre Hospitalier Universitaire De Nice

Address
lock Available on a paid plan

Nervous System Diseases

At Centre Hospitalier Universitaire De Nice, the Neurology department is involved in research on Nervous System Diseases, with a strong focus on conditions such as multiple sclerosis, Parkinson’s disease, generalized myasthenia gravis, and facioscapulohumeral muscular dystrophy. These studies are designed to assess new treatment options, compare established therapies, and better understand how to slow disease progression and improve daily function.

  • Testing therapies for multiple sclerosis to reduce disease activity and support long-term control
  • Evaluating treatment approaches for Parkinson’s disease to delay motor decline
  • Studying new options for myasthenia gravis and other neuromuscular disorders

This area reflects a broad effort to improve both symptom management and long-term outcomes for people living with complex neurological conditions.

Cardiovascular and Stroke Research

The site is also active in Cardiovascular Diseases, including studies in acute coronary syndrome, atherosclerotic cardiovascular disease, atrial fibrillation, and stroke prevention. Research here aims to test whether new treatments can lower the risk of heart attack, stroke, and other major cardiovascular events while balancing safety concerns such as bleeding risk.

  • Assessing therapies to reduce recurrent events after acute coronary syndrome
  • Improving prevention of ischemic stroke in high-risk patients
  • Comparing treatment strategies for atrial fibrillation to prevent stroke or systemic embolism

These studies support better prevention and long-term management of serious vascular disease in patients at elevated risk.

Respiratory and Interstitial Lung Disease

Clinical trials at this hospital in Nice include important work in Respiratory Tract Diseases, especially idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, interstitial lung disease, bronchiectasis, and asthma. The main goal is to evaluate therapies that may improve lung function, reduce flare-ups, and slow worsening of chronic lung disorders.

  • Testing treatments for pulmonary fibrosis and related scarring conditions
  • Studying care options for bronchiectasis and early airway infections
  • Evaluating new approaches for severe asthma in children and adolescents

This research area is centered on finding better ways to preserve breathing capacity and quality of life in patients with chronic respiratory disease.

Rheumatology and Immune-Mediated Disease

The research portfolio also covers Immune System Diseases and Musculoskeletal Diseases, with studies in rheumatoid arthritis, dermatomyositis, and systemic sclerosis-associated interstitial lung disease. These trials are focused on comparing treatment strategies, reducing inflammation, and improving symptoms and physical function in autoimmune conditions.

  • Comparing therapies for rheumatoid arthritis to improve remission rates
  • Exploring new treatments for dermatomyositis and related muscle inflammation
  • Assessing immune-targeted approaches in systemic sclerosis-related lung involvement

This work highlights the site’s role in advancing care for chronic inflammatory diseases that can affect both joints and internal organs.

Other Specialized Clinical Research

Beyond the major disease groups, Centre Hospitalier Universitaire De Nice contributes to studies in Analytical, Diagnostic and Therapeutic Techniques and Equipment, including research aimed at improving procedures and treatment support. One example is work on kidney stone management, where trials assess whether new supportive strategies can improve stone clearance and recovery after treatment.

  • Improving outcomes in kidney stone treatment
  • Supporting better procedural results in urological care
  • Evaluating practical ways to enhance treatment effectiveness across specialized care settings

This mixed research activity shows a broad commitment to refining patient care across several clinical fields, not only disease treatment but also the tools and approaches used to deliver it.

Site Overview

assignment
67
connected trials
corporate_fare
51
sponsors
science
113
IMPs

Activity Indicator

Last 6 months

8
Trials started
-11% vs previous period.
9
Trials started 6–12 months ago
67
Total trials linked
Highly Active
trending_downDeclining-11%
1
1
2
3
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 15 therapeutic areas and 15 of 113 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 112 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
39
Sponsors (total)
51
Active sponsors
34

Sponsor Network

Top 34 by active trials.

lock +33 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +12 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 978 other sites in France

description
Trial volume
67
Outperforms 90% of sites
public
Therapeutic diversity
15areas
Outperforms 90% of sites
groups
Sponsor diversity
51sponsors
Outperforms 93% of sites

Therapeutic Area Benchmark — France

Select a therapeutic area to compare against other sites in France.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: France

Market Share

Country: France

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Centre Hospitalier Universitaire De Nice

lock Showing 1 of 67 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Multicentre, Randomised, Double-blind, Parallel Group, Placebocontrolled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients with Severe Eosinophilic Asthma (DOMINICA)AstraZeneca ABPhase IIINot RecruitingJun 2023

IMP list

lock Showing 1 of 113 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Cytarabine4Unknown2022-09-152026-04-02

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.